Biogen has reported positive outcomes from a mid-stage study of its lupus-targeting drug, particularly in terms of skin clearance.
These results may have significant implications for the treatment landscape of lupus, a chronic autoimmune disease affecting many patients.
The findings align with ongoing advancements in biotech, highlighting the importance of continued research and development in this therapeutic area.